⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Official Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study ID: NCT02369874

Study Description

Brief Summary: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.

Detailed Description: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population. The main objectives of the study are to: * assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC in patients with squamous cell carcinoma of the head and neck (SCCHN), in terms of overall survival (OS), regardless of PDL-1 status * assess the efficacy of MEDI4736 monotherapy versus SOC in patients with SCCHN, in terms of OS, regardless of PDL-1 status Patients will undergo a screening assessment on their tumor tissue sample to determine PD-L1 expression per a pre-specified cut-off level. Patients with ≥25% of tumor cells with membrane staining will be considered PD-L1 positive while those with 0% to 24% of tumor cells with membrane staining will be considered PD-L1 negative. Based on the underlying PD-L1 status, patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or SoC therapy. Patients who discontinue treatment in 1 treatment group may not switch to treatment in a different group. Stratification factors include PD-L1 status, human papillomavirus status, (in patients with oropharyngeal cancer only), and smoking status. Tumor assessments will be performed every 8 weeks until objective tumor response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Research Site, Tucson, Arizona, United States

Research Site, Fullerton, California, United States

Research Site, Los Angeles, California, United States

Research Site, Redondo Beach, California, United States

Research Site, Stanford, California, United States

Research Site, Denver, Colorado, United States

Research Site, Newark, Delaware, United States

Research Site, Miami Beach, Florida, United States

Research Site, Orlando, Florida, United States

Research Site, Atlanta, Georgia, United States

Research Site, Evanston, Illinois, United States

Research Site, Lexington, Kentucky, United States

Research Site, Boston, Massachusetts, United States

Research Site, Rochester, New York, United States

Research Site, Rochester, New York, United States

Research Site, Winston-Salem, North Carolina, United States

Research Site, Pittsburgh, Pennsylvania, United States

Research Site, Germantown, Tennessee, United States

Research Site, Nashville, Tennessee, United States

Research Site, Dallas, Texas, United States

Research Site, Dallas, Texas, United States

Research Site, McAllen, Texas, United States

Research Site, Norfolk, Virginia, United States

Research Site, Caba, , Argentina

Research Site, San Miguel de Tucuman, , Argentina

Research Site, Adelaide, , Australia

Research Site, Heidelberg, , Australia

Research Site, Melbourne, , Australia

Research Site, St Leonards, , Australia

Research Site, Woolloongabba, , Australia

Research Site, Brussels, , Belgium

Research Site, Bruxelles, , Belgium

Research Site, Charleroi, , Belgium

Research Site, Kortrijk, , Belgium

Research Site, Leuven, , Belgium

Research Site, Namur, , Belgium

Research Site, Barretos, , Brazil

Research Site, Curitiba, , Brazil

Research Site, Porto Alegre, , Brazil

Research Site, Porto Alegre, , Brazil

Research Site, Rio de Janeiro, , Brazil

Research Site, Santo Andre, , Brazil

Research Site, São José do Rio Preto, , Brazil

Research Site, São Paulo, , Brazil

Research Site, Shumen, , Bulgaria

Research Site, Sofia, , Bulgaria

Research Site, Varna, , Bulgaria

Research Site, Temuco, , Chile

Research Site, Osijek, , Croatia

Research Site, Zagreb, , Croatia

Research Site, Olomouc, , Czechia

Research Site, Zlin, , Czechia

Research Site, Angers, , France

Research Site, Bordeaux, , France

Research Site, Dijon, , France

Research Site, Le Mans, , France

Research Site, Lyon Cedex 08, , France

Research Site, Montpellier Cedex 5, , France

Research Site, Paris Cedex 5, , France

Research Site, Plerin SUR MER, , France

Research Site, Rouen, , France

Research Site, St Grégoire, , France

Research Site, Strasbourg Cedex, , France

Research Site, Villejuif Cedex, , France

Research Site, Lorient Cedex, , Georgia

Research Site, Berlin, , Germany

Research Site, Essen, , Germany

Research Site, Halle, , Germany

Research Site, Hannover, , Germany

Research Site, Heidelberg, , Germany

Research Site, Leipzig, , Germany

Research Site, München, , Germany

Research Site, Potsdam, , Germany

Research Site, Budapest, , Hungary

Research Site, Budapest, , Hungary

Research Site, Budapest, , Hungary

Research Site, Gyor, , Hungary

Research Site, Kecskemét, , Hungary

Research Site, Haifa, , Israel

Research Site, Jerusalem, , Israel

Research Site, Petach-Tikva, , Israel

Research Site, Tel Aviv, , Israel

Research Site, Tel Hashomer, , Israel

Research Site, Aosta, , Italy

Research Site, Bologna, , Italy

Research Site, Gallarate, , Italy

Research Site, Legnago, , Italy

Research Site, Milano, , Italy

Research Site, Napoli, , Italy

Research Site, Pavia, , Italy

Research Site, Roma, , Italy

Research Site, Siena, , Italy

Research Site, Chuo-ku, , Japan

Research Site, Fukuoka-shi, , Japan

Research Site, Hirakata-shi, , Japan

Research Site, Isehara-shi, , Japan

Research Site, Kashiwa, , Japan

Research Site, Kitaadachi-gun, , Japan

Research Site, Kobe-shi, , Japan

Research Site, Koto-ku, , Japan

Research Site, Matsuyama-shi, , Japan

Research Site, Nagoya, , Japan

Research Site, Natori-shi, , Japan

Research Site, Okayama, , Japan

Research Site, Osakasayama, , Japan

Research Site, Osaka, , Japan

Research Site, Sapporo, , Japan

Research Site, Sapporo, , Japan

Research Site, Shimotsuke-shi, , Japan

Research Site, Sunto-gun, , Japan

Research Site, Takatsuki-shi, , Japan

Research Site, Yokohama-shi, , Japan

Research Site, Yokohama, , Japan

Research Site, Daegu, , Korea, Republic of

Research Site, Goyang-si, , Korea, Republic of

Research Site, Seoul, , Korea, Republic of

Research Site, Seoul, , Korea, Republic of

Research Site, Suwon, , Korea, Republic of

Research Site, Kraków, , Poland

Research Site, Poznań, , Poland

Research Site, Łódź, , Poland

Research Site, Baia Mare, , Romania

Research Site, Brasov, , Romania

Research Site, Cluj-Napoca, , Romania

Research Site, Cluj, , Romania

Research Site, Craiova, , Romania

Research Site, Arkhangelsk, , Russian Federation

Research Site, Chelyabinsk, , Russian Federation

Research Site, Kursk, , Russian Federation

Research Site, Moscow, , Russian Federation

Research Site, Moscow, , Russian Federation

Research Site, Moscow, , Russian Federation

Research Site, Moscow, , Russian Federation

Research Site, Moscow, , Russian Federation

Research Site, Nizhniy Novgorod, , Russian Federation

Research Site, Omsk, , Russian Federation

Research Site, Pyatigorsk, , Russian Federation

Research Site, Saint Petersburg, , Russian Federation

Research Site, Saint-Petersburg, , Russian Federation

Research Site, Sankt-Peterburg, , Russian Federation

Research Site, Sochi, , Russian Federation

Research Site, Ufa, , Russian Federation

Research Site, Vladimir, , Russian Federation

Research Site, Belgrade, , Serbia

Research Site, Belgrad, , Serbia

Research Site, Kragujevac, , Serbia

Research Site, Nis, , Serbia

Research Site, Sremska Kamenica, , Serbia

Research Site, Barcelona, , Spain

Research Site, Barcelona, , Spain

Research Site, L'Hospitalet de Llobregat, , Spain

Research Site, Madrid, , Spain

Research Site, Madrid, , Spain

Research Site, Madrid, , Spain

Research Site, Malaga, , Spain

Research Site, Marbella, , Spain

Research Site, Pamplona, , Spain

Research Site, Valencia, , Spain

Research Site, Valencia, , Spain

Research Site, Zaragoza, , Spain

Research Site, Kaohsiung, , Taiwan

Research Site, Taipei, , Taiwan

Research Site, Taipei, , Taiwan

Research Site, Taoynan, , Taiwan

Research Site, Dnipro, , Ukraine

Research Site, Kyiv, , Ukraine

Research Site, Sumy, , Ukraine

Research Site, Uzhhorod, , Ukraine

Research Site, Zaporizhzhia, , Ukraine

Contact Details

Name: Nassim Morsli, MD

Affiliation: Medical Director AstraZeneca

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: